Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.
説明 | Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control. |
別名 | ONO2235 |
分子量 | 319.4 |
分子式 | C15H13NO3S2 |
CAS No. | 82159-09-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 9 mg/mL (28.18 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Epalrestat 82159-09-9 Endocrinology/Hormones Metabolism Reductase ONO2235 inhibit Aldose Reductase Inhibitor ONO 2235 ONO-2235 inhibitor